Introduction

OTC Products Occupy One of the Most Visible and Closely Scrutinized Consumer Markets

Over-the-counter drugs are products intended for consumers to use without a prescription when the product is appropriately formulated, labeled and marketed. They include familiar items sold in pharmacies, supermarkets, beauty stores, convenience stores and online marketplaces. Sunscreens, antidandruff shampoos, fluoride toothpastes, antiperspirant deodorants, skin protectants, acne treatments, menstrual symptom products, cough and allergy medicines, nighttime sleep aids and antacids are only a portion of the categories that may be regulated as OTC drugs in the United States.

The expression “OTC cosmetic” is widely used in commerce to describe personal-care or beauty products that are also drugs because they make therapeutic claims or affect the structure or function of the body. Under U.S. law, however, a product may be a cosmetic, a drug, or both. A regular shampoo intended only to cleanse hair is generally a cosmetic. An antidandruff shampoo is also a drug because it is intended to control dandruff. A deodorant intended only to mask odor may be a cosmetic, while an antiperspirant that reduces perspiration is regulated as a drug and may also be a cosmetic. A moisturizer with sunscreen claims, an acne cleanser, and fluoride toothpaste can similarly fall under both legal frameworks.

This distinction matters because drug requirements are substantially more demanding than ordinary cosmetic requirements. Drug establishment registration, drug listing, National Drug Code data, active ingredient conformity, current good manufacturing practice, Drug Facts labeling and OTC monograph compliance may be required. Foreign facilities must also consider a U.S. Agent, electronic submissions, import-entry data and the risk of detention or refusal when records do not match the imported shipment.

Digital commerce adds another layer of risk. Amazon product pages, YouTube demonstrations, Facebook advertisements, TikTok videos, livestreams, affiliate posts and influencer testimonials can establish or expand a product’s intended use. A label that appears conservative may not protect a company when its online marketing promises to cure eczema, eliminate acne permanently, prevent infection, reverse hair loss, treat asthma or provide another drug claim that is unsupported or outside an applicable OTC monograph.

Chapter 1

Understanding OTC Drugs, Cosmetics and Combination Drug-Cosmetic Products

Compliance warning: Intended use can be shown by the package, website, social-media content, product category, testimonials, before-and-after images, influencer scripts, hashtags, search terms, directions and the circumstances surrounding distribution.

Chapter 2

OTC Drug Monographs and the Two Main Routes to Market

In the United States, a nonprescription drug generally reaches the market through an approved drug application or through the OTC drug monograph system. An OTC monograph functions like a regulatory standard for a therapeutic category. It addresses conditions under which covered products may be marketed, including active ingredients, strengths, dosage forms, routes of administration, indications, warnings, directions and other labeling conditions.

The modern monograph system was reformed by the CARES Act. FDA can use administrative orders to add, revise or remove monograph conditions as scientific and safety information develops. Companies therefore should not rely on an old printed monograph, an outdated consultant memo or a competitor’s package. The applicable final administrative orders, deemed final orders, proposed orders, guidance documents and other current FDA materials must be reviewed for the specific category and formulation.

Private-label companies must understand that copying a competing label is not a regulatory strategy. The competitor may be using an approved application, may have different manufacturing data, may have discontinued a claim, or may itself be noncompliant. A documented regulatory assessment should connect every active ingredient and every claim to the applicable legal pathway.

Chapter 3

Major OTC and OTC Cosmetic Categories

Chapter 4

Manufacturing, Registration, Listing and Labeling

Domestic and foreign establishments that manufacture, prepare, propagate, compound, process, repack or relabel drugs for U.S. commercial distribution may have FDA drug establishment registration and listing obligations. Registration is not product approval, certification or evidence that FDA has endorsed the facility. It is a statutory submission that must be accurate, current and supported by the facility’s actual operations.

Drug establishment registration is renewed annually, and marketed drug listing information must be submitted and maintained electronically in Structured Product Labeling format. The listing data must accurately identify the labeler, establishment roles, active and inactive ingredients, dosage form, route, marketing category, package configurations and labeling. Foreign establishments generally must identify a U.S. Agent for communications with FDA.

The Drug Facts label is a standardized consumer communication tool. It typically presents active ingredients and purposes, uses, warnings, directions, other information and inactive ingredients in a required sequence and format. Small packages, multi-language labels, kits, combination packages and outer cartons require advance planning. A cosmetically attractive design cannot override mandatory drug labeling.

Manufacturers also need an appropriate quality system and compliance with drug current good manufacturing practice. Written procedures, component controls, production records, laboratory testing, stability support, packaging controls, complaint handling, investigations and corrective actions are essential. Private-label owners should qualify contract manufacturers and should not assume that a certificate displaying an FDA logo substitutes for due diligence.

Chapter 5

Influencers, YouTube, Amazon, Facebook and TikTok

Online marketing is not separate from FDA compliance. Product pages and social-media content can be evidence of intended use. When a brand’s Amazon title says “eczema healing cream,” a YouTube video promises that a supplement-like syrup “stops asthma attacks,” or a TikTok creator claims that a cosmetic serum “kills acne bacteria,” the company may create drug claims beyond the product’s lawful status.

Brand owners should implement a written digital-claims policy covering employees, agencies, affiliates, distributors and influencers. Approved claim libraries, prohibited-claim examples, required disclosures, review workflows and record retention reduce the risk that a marketing partner improvises medically significant statements during a livestream or product demonstration.

A platform’s acceptance of a listing is not FDA clearance. Marketplace algorithms and automated moderation may miss regulatory violations or may later remove a product that previously sold for months. The company remains responsible for the legal status, safety, labeling and advertising of the product.

Chapter 6

International Manufacturers and U.S. Import Compliance

European, Asian, Latin American and African companies often enter the United States with products already marketed under local cosmetic, medicinal, natural-health or quasi-drug frameworks. The foreign classification does not control the U.S. classification. A product sold as a cosmetic in one country may be an OTC drug in the United States because of its ingredients or claims. Conversely, wording permitted by a foreign ministry or notified body may not fit an FDA monograph.

Before the first shipment, the exporter and U.S. importer should verify the legal manufacturer, labeler, registered establishments, U.S. Agent, product listing, NDC data, label version, manufacturer address and import-entry identifiers. Commercial invoices, packing lists and customs data should describe the product consistently. Discrepancies between the physical label, FDA listing and entry information can delay review and contribute to detention.

Imported products that appear adulterated, misbranded or unapproved may be detained, refused, re-exported or destroyed. A foreign firm should have an escalation plan before a shipment is placed on hold. The plan should identify responsible personnel, document repositories, the customs broker, importer, U.S. Agent, regulatory consultant and decision authority for corrective action.

Chapter 7

Common Violations and Enforcement Risks

Potential consequences include import detention, refusal, warning letters, recalls, seizure, injunction, civil or criminal exposure, marketplace suspension, payment holds, destruction costs and loss of distributor confidence. Corrective action after enforcement is generally more expensive than premarket review.

Chapter 8

Services Provided by U.S. FDA Consultants

An experienced FDA consultant can coordinate the regulatory work required to move an OTC drug or drug-cosmetic product from concept to lawful U.S. commercialization. The consultant does not replace the manufacturer’s legal responsibility and cannot guarantee FDA acceptance, but can identify gaps, organize submissions and reduce avoidable errors.

Consultants can also support supplier qualification, quality agreements, standard operating procedures, complaint systems, adverse-event escalation, mock inspections, records review and training for marketing teams. For global companies, a coordinated review avoids contradictory decisions by the manufacturer, brand owner, importer, distributor and advertising agency.

Chapter 9

A Practical Premarket Compliance Checklist

• Confirm the U.S. regulatory classification based on intended use, not only the foreign classification.
• Identify the precise OTC monograph or drug application pathway for every therapeutic claim.
• Verify active ingredients, strengths, dosage form, route, directions and warnings.
• Review inactive ingredients, color additives, allergens, flavors and packaging compatibility.
• Confirm that all manufacturing, repacking and relabeling establishments are correctly registered.
• Prepare and validate electronic drug listing data and NDC package configurations.
• Develop compliant Drug Facts and principal display panel labeling.
• Check cosmetics requirements as well when the product is both a cosmetic and a drug.
• Review Amazon, Facebook, TikTok, YouTube and website content before publication.
• Train influencers and affiliates, require material-connection disclosures and monitor live content.
• Qualify contract manufacturers and obtain adequate quality and testing documentation.
• Confirm import-entry data, importer responsibilities, U.S. Agent details and shipment records.
• Create complaint, adverse-event, recall and enforcement-response procedures.
• Schedule annual registration renewal, listing certification and ongoing label maintenance.

Conclusion

OTC Success Requires Regulatory Discipline Across the Entire Supply Chain

The U.S. OTC market offers significant opportunities for domestic companies and for manufacturers and exporters from Europe, Asia, Latin America and Africa. Yet consumer familiarity with sunscreens, acne products, antiperspirants, cough medicines, sleep aids and antacids should not be mistaken for regulatory simplicity.

A compliant launch begins with product classification and continues through monograph analysis, formula review, manufacturing controls, establishment registration, drug listing, labeling, import documentation and advertising oversight. Every public statement about the product should be consistent with its lawful status. That includes the package, Amazon page, distributor catalog, YouTube demonstration, Facebook campaign, TikTok livestream and influencer testimonial.

Companies that build compliance into product development are better positioned to avoid relabeling, shipment delays, marketplace suspensions and enforcement costs. Companies that treat registration as a one-time certificate, or rely on copied claims and informal marketplace practices, may discover regulatory problems only after inventory has been produced and shipped.